JPMorgan Chase restated their overweight rating on shares of AstraZeneca (LON:AZN) in a report published on Tuesday morning, Marketbeat reports. JPMorgan Chase currently has a GBX 5,500 ($74.61) target price on the biopharmaceutical company’s stock.
Several other equities research analysts also recently weighed in on the company. Jefferies Group increased their price target on AstraZeneca from GBX 5,600 ($75.96) to GBX 5,950 ($80.71) and gave the stock a buy rating in a report on Monday. Barclays set a GBX 6,500 ($88.17) price target on AstraZeneca and gave the stock a buy rating in a report on Friday, May 11th. Shore Capital reissued a hold rating on shares of AstraZeneca in a report on Friday, May 11th. Credit Suisse Group reissued an outperform rating on shares of AstraZeneca in a report on Friday, May 4th. Finally, Goldman Sachs set a GBX 3,750 ($50.87) target price on AstraZeneca and gave the company a sell rating in a report on Tuesday, April 24th. Four analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the company. AstraZeneca currently has a consensus rating of Hold and an average target price of GBX 5,255.78 ($71.29).
Shares of AstraZeneca opened at GBX 5,208 ($70.65) on Tuesday, according to Marketbeat. AstraZeneca has a 1-year low of GBX 4,260 ($57.79) and a 1-year high of GBX 5,520 ($74.88).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.